$TLC News

Last published 4y ago

4y agoENDP TLCTLC Announces TLC599 Agreement with EndoGlobeNewswireSOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, June 13, 2022 (GLOBE NEWSWIRE) -- TLC BioSciences (TLC), a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical need, today announced that it has
4y agoTLCTLC BioSciences Announces Publication of TLC599 Phase II Results in Arthritis Research & TherapyGlobeNewswireSOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, March 07, 2022 (GLOBE NEWSWIRE) -- TLC BioSciences, a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical need, today announced that detailed re
5y agoTLCTLC Announces Voluntary Delisting and Deregistration of American Depositary SharesGlobeNewswireThis communication does not constitute an offer of any securities for sale or subscription or a solicitation of an offer to purchase or subscribe to any securities in any jurisdiction. The securities to be issued pursuant to the stock swap transaction
5y agoTLCTLC Reports Second Quarter 2021 Financial Results and Provides Business UpdateGlobeNewswireSOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, Aug. 12, 2021 (GLOBE NEWSWIRE) -- TLC, a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical need, today announced financial results for the sec
5y agoTLCTLC Announces Details of Stock Swap TransactionsGlobeNewswireTAIPEI, Taiwan, July 05, 2021 (GLOBE NEWSWIRE) -- Taiwan Liposome Company (NASDAQ:TLC, TWO: 4152, "the company"))), a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical need, today announced
5y agoTLCTLC and Zydus Enter Agreement to Launch AmphoTLC™ in IndiaGlobeNewswireSOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, May 26, 2021 (GLOBE NEWSWIRE) -- TLC (NASDAQ:TLC, TWO: 4152))), a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical need, and Zydus Healthcare
5y agoTLCTLC Announces Approval of New Drug Application of Liposomal Amphotericin B in IndiaGlobeNewswireSOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, May 25, 2021 (GLOBE NEWSWIRE) -- TLC (NASDAQ:TLC, TWO: 4152))), a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical need, today announced that
5y agoTLCInspirMed Highlights Encouraging Data on ISPM21 and ISPM19 – Inhalable Liposome Formulations of Antiviral Drugs for COVID-19GlobeNewswireSOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, May 23, 2021 (GLOBE NEWSWIRE) -- InspirMed Inc., a subsidiary of TLC (NASDAQ:TLC, TWO: 4152))) that specializes in the development of proprietary inhalable liposome formulation programs, recently presente
5y agoTLCTLC Reports First Quarter 2021 Financial Results and Provides Business UpdateGlobeNewswireSOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, May 14, 2021 (GLOBE NEWSWIRE) -- TLC (NASDAQ:TLC, TWO: 4152))), a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical need, today announced fina
5y agoTLCTLC Earns Highest Ranking in Corporate Governance Evaluation Seven Years RunningGlobeNewswireSOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, May 03, 2021 (GLOBE NEWSWIRE) -- TLC (NASDAQ:TLC, TWO: 4152))), a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical need, today announced that
5y agoTLCInspirMed to Present at the 23rd International Society for Aerosols in Medicine (ISAM) CongressGlobeNewswireSOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, April 26, 2021 (GLOBE NEWSWIRE) -- InspirMed Inc., a subsidiary of TLC (NASDAQ:TLC, TWO: 4152))) that specializes in the development of inhalable liposome formulation programs, announced today that a late
5y agoTLCNew patent granted for: Pharmaceutical Compositions for Intraarticular DeliveryUS Patent Applications (USPTO)The present invention provides methods of treating arthritis. A sustained release composition comprising liposomes and one or more therapeutic agent or a pharmaceutically acceptable salt thereof is administered to a subject in need thereof. The liposomes may be in an aqueous suspension. The sustained release composition can be administered intraarticularly.
5y agoTLCTLC to Present at Upcoming Virtual Investor ConferencesGlobeNewswireSOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, March 02, 2021 (GLOBE NEWSWIRE) -- TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company developing novel nanomedicines to...
5y agoTLCTLC Reports Fiscal Year End 2020 Financial Results and Provides Business UpdateGlobeNewswireSOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, Feb. 05, 2021 (GLOBE NEWSWIRE) -- TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company developing novel nanomedicines...
5y agoTLCTLC Announces Completion of US$15 Million Financing for Subsidiary InspirMed Inc.GlobeNewswireSOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, Jan. 04, 2021 (GLOBE NEWSWIRE) -- TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company developing novel nanomedicines to...
5y agoTLCTLC Announces Full Patient Enrollment in EXCELLENCE Trial of TLC599 for Osteoarthritis PainGlobeNewswireSOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, Dec. 28, 2020 (GLOBE NEWSWIRE) -- TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company developing novel nanomedicines to...
5y agoTLCTLC Provides Corporate Update at Investor ConferenceGlobeNewswirePatient enrollment of EXCELLENCE pivotal trial reaches 98% SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, Dec. 18, 2020 (GLOBE NEWSWIRE) -- TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage...
5y agoTLCNew patent application published for: Sustained-Release Triptan Compositions and Method of Use the Same Through Subdermal Route or the LikeUS Patent Applications (USPTO)
6y agoTLCTLC Announces Acceptance of Manuscript on Anti-COVID-19 Program by Clinical and Translational Science JournalGlobeNewswireSOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, Nov. 03, 2020 (GLOBE NEWSWIRE) -- TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company developing novel nanomedicines to...
6y agoTLCTLC Reports Third Quarter 2020 Financial Results and Provides Business UpdateGlobeNewswireSOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, Oct. 28, 2020 (GLOBE NEWSWIRE) -- TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company developing novel nanomedicines to...
6y agoTLCTLC Announces the Appointment of Thomas H. Bliss, Jr., MBA, as Chief Business OfficerGlobeNewswireSOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, Oct. 21, 2020 (GLOBE NEWSWIRE) -- TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage, specialty pharmaceutical company developing novel nanomedicines to...
6y agoTLCTLC Enrolls First Subject in Phase I Clinical Trial of Inhalable Anti-COVID-19 Program (TLC19)GlobeNewswireSOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, Oct. 14, 2020 (GLOBE NEWSWIRE) -- TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company developing novel nanomedicines to...
6y agoTLCTLC Receives Australian and Taiwan Approval to Initiate Phase I Clinical Trial of TLC19 Inhalable Liposomal Hydroxychloroquine for COVID-19GlobeNewswireSOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, Oct. 07, 2020 (GLOBE NEWSWIRE) -- TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company developing novel nanomedicines to...
6y agoTLCTLC to Present at Oppenheimer Fall Healthcare Life Sciences & Med Tech SummitGlobeNewswireSOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, Sept. 21, 2020 (GLOBE NEWSWIRE) -- TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company developing novel nanomedicines to...
6y agoTLCTLC to Present at Cantor Virtual Global Healthcare ConferenceGlobeNewswireSOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, Sept. 11, 2020 (GLOBE NEWSWIRE) -- TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company developing novel nanomedicines to...
6y agoTLCTLC to Present at HC Wainwright & Co. 22nd Annual Global Investment ConferenceGlobeNewswireSOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, Sept. 09, 2020 (GLOBE NEWSWIRE) -- TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company developing novel nanomedicines to...
6y agoTLCTLC to Present at Baird’s 2020 Global Healthcare ConferenceGlobeNewswireSOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, Sept. 03, 2020 (GLOBE NEWSWIRE) -- TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company developing novel nanomedicines to...
6y agoTLCTLC and 3SBio Announce Acceptance of Marketing Authorization Application for Ampholipad™ in ChinaGlobeNewswireSOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, Aug. 26, 2020 (GLOBE NEWSWIRE) -- TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company developing novel nanomedicines to...
6y agoTLCTLC Submits Investigational New Drug (IND) Application for TLC19 Inhalable Liposomal Hydroxychloroquine for COVID-19GlobeNewswire1% of oral dose for 30-fold lung exposure and reduced cardiotoxicityA cost-effective, easily accessible, user-friendly potential treatment/prevention option SOUTH SAN FRANCISCO, Calif. and TAIPEI,...
6y agoTLCTLC Reports Second Quarter 2020 Financial Results and Provides Business UpdateGlobeNewswireSOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, Aug. 05, 2020 (GLOBE NEWSWIRE) -- TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company developing novel nanomedicines to...
6y agoTLCManuscript Describes How TLC’s Inhalable Liposomal Hydroxychloroquine May Provide Clinical Benefit and Serve as Potential Treatment for COVID-19GlobeNewswireSOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan , July 15, 2020 (GLOBE NEWSWIRE) -- TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company developing novel nanomedicines to...
6y agoTLCTLC Announces Completion of US$23 Million FinancingGlobeNewswireSOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, June 30, 2020 (GLOBE NEWSWIRE) -- TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company developing novel nanomedicines to...
6y agoTLCTLC Announces Topline Results for TLC590 Phase II Trial for Postsurgical Pain Management following BunionectomyGlobeNewswireSOUTH SAN FRANCISCO, CA and TAIPEI, Taiwan, May 31, 2020 (GLOBE NEWSWIRE) -- TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target...
6y agoTLCNew patent granted for: Ophthalmic Drug Delivery System Containing Phospholipid and CholesterolUS Patent Applications (USPTO)An ophthalmic drug delivery system that contains phospholipid and cholesterol for prolonging drug lifetime in the eyes.
6y agoTLCTLC Highlights Findings in Abstract Accepted at Osteoarthritis Research Society International (OARSI) 2020 and Published in Osteoarthritis and CartilageGlobeNewswireSOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, May 18, 2020 (GLOBE NEWSWIRE) -- TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company developing novel nanomedicines to...
6y agoTLCTLC Reports First Quarter 2020 Financial Results and Provides Business UpdateGlobeNewswireSOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, May 13, 2020 (GLOBE NEWSWIRE) -- TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company developing novel nanomedicines to...
6y agoTLCTLC Earns Highest Ranking in Corporate Governance Evaluation Six Years in a RowGlobeNewswireSOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, May 04, 2020 (GLOBE NEWSWIRE) -- TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company developing novel nanomedicines to...
6y agoTLCTLC Announces Early Completion of Patient Enrollment in TLC590 Phase II Clinical Trial following BunionectomyGlobeNewswireSOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, Feb. 12, 2020 (GLOBE NEWSWIRE) -- TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company developing novel nanomedicines to...
6y agoTLCTLC Reports Fiscal Year End 2019 Financial Results and Provides Business UpdateGlobeNewswireSOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, Feb. 11, 2020 (GLOBE NEWSWIRE) -- TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company developing novel nanomedicines to...
6y agoTLCTLC Announces Dosing of First Patients in Part 2 of TLC590 Phase II Trial for Postsurgical Pain following BunionectomyGlobeNewswirePart 2 will dose ~150 patients with TLC590, bupivacaine, or placeboPrimary endpoint: AUC0-72 on numerical pain rating scaleEnrollment of all patients to take ~3 months SOUTH SAN FRANCISCO, CA...
6y agoTLCTLC to Present at 38th Annual JP Morgan Healthcare ConferenceGlobeNewswireSOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, Jan. 02, 2020 (GLOBE NEWSWIRE) -- TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company developing novel nanomedicines to...
6y agoTLCTLC Announces First Patient Enrollment in EXCELLENCE Trial Evaluating Single and Repeat Administrations of TLC599GlobeNewswirePhase III clinical trial of TLC599 to recruit 500 patients with moderate to severe symptomatic knee osteoarthritis Patients can receive two injections of placebo or drugPatient enrollment expected to...
7y agoTLCTLC Announces Completion of US$27 Million FinancingGlobeNewswireSOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, Oct. 24, 2019 (GLOBE NEWSWIRE) -- TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company developing novel nanomedicines to...
7y agoTLCTLC Reports Third Quarter 2019 Financial Results and Provides Business UpdateGlobeNewswireSOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, Oct. 22, 2019 (GLOBE NEWSWIRE) -- TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company developing novel nanomedicines to...
7y agoTLCTLC Presents Clinical and Preclinical Data of TLC590 at ANESTHESIOLOGY® Annual Meeting and in International Journal of NanomedicineGlobeNewswireSOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, Oct. 21, 2019 (GLOBE NEWSWIRE) -- TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company developing novel nanomedicines to...
7y agoTLCTLC Appoints Vincent Chang, PhD, as Vice President of Manufacturing DevelopmentGlobeNewswireSOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, Oct. 20, 2019 (GLOBE NEWSWIRE) -- TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company dedicated to the development and...
7y agoTLCTLC to Present Potential Cartilage-Protecting Effects of TLC599 on the Knee at 2019 ACR Annual MeetingGlobeNewswireSOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, Oct. 07, 2019 (GLOBE NEWSWIRE) -- TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company dedicated to the development and...
7y agoTLCTLC Announces Initiation of Phase III Pivotal Clinical Trial of TLC599 for the Treatment of Osteoarthritis Knee PainGlobeNewswire- Phase II results showed statistically significant pain relief through 24 weeks- Phase III to evaluate efficacy of single and repeated doses up to 52 weeks SOUTH SAN FRANCISCO, Calif. and TAIPEI,...
7y agoTLCTLC to Present Preclinical Data on TLC178 at ESMO 2019GlobeNewswireSOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, Sept. 23, 2019 (GLOBE NEWSWIRE) -- TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company dedicated to the development and...
7y agoTLCTLC to Present as Panelist among Key Opinion Leaders at the BTIG Pain Management ForumGlobeNewswireSOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, Sept. 03, 2019 (GLOBE NEWSWIRE) -- TLC (Nasdaq: TLC, TWO: 4152) announced today that the Company’s management team has been invited to participate in...